Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.
Saved in:
| Title: | Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. |
|---|---|
| Authors: | Satake N; Department of Pediatrics.; Stem Cell Program., Duong C; Department of Pediatrics.; Stem Cell Program., Yoshida S; Department of Pediatrics.; Stem Cell Program., Oestergaard M; Isis Pharmaceuticals., Chen C; Department of Pediatrics.; Stem Cell Program., Peralta R; Isis Pharmaceuticals., Guo S; Isis Pharmaceuticals., Seth PP; Isis Pharmaceuticals., Li Y; Department of Public Health Sciences., Beckett L; Department of Public Health Sciences., Chung J; Department of Pediatrics., Nolta J; Stem Cell Program., Nitin N; Departments of Food Science & Technology and Biological & Agricultural Engineering., Tuscano JM; Department of Internal Medicine, University of California, Davis. |
| Source: | Molecular medicine (Cambridge, Mass.) [Mol Med] 2016 Oct; Vol. 22, pp. 632-642. Date of Electronic Publication: 2016 Jul 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 9501023 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-3658 (Electronic) Linking ISSN: 10761551 NLM ISO Abbreviation: Mol Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
